Score Overview
Explore the 2021 public Archive ranking →
Where Eli Lilly and Company has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- LLY
1996: 46.2% · 2021: 20.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 1.18K | — |
1 Year2025-09-26 | $ 720.00 | 64.55% |
5 Years2021-09-28 | $ 211.80 | 459.39% |
10 Years2016-09-28 | $ 69.03 | 17x |
20 Years2006-09-28 | $ 32.65 | 36x |
30 Years1996-09-27 | $ 15.39 | 76x |
All Time1978-01-13 | $ 0.58 | 2041x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1978-01-13 |
|---|---|---|---|---|---|---|---|
| Price | $ 1.18K | $ 720.00 | $ 211.80 | $ 69.03 | $ 32.65 | $ 15.39 | $ 0.58 |
| Return | — | 64.55% | 459.39% | 17x | 36x | 76x | 2041x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 79.66B | $ 26.70B | $ 8.95B |
| 2025 | $ 65.17B | $ 20.63B | $ 7.26B |
| 2024 | $ 45.04B | $ 10.59B | $ 3.42B |
| 2023 | $ 34.12B | $ 5.24B | $ 2.92B |
| 2022 | $ 28.54B | $ 6.24B | $ 2.21B |
| 2021 | $ 28.31B | $ 5.58B | $ 3.90B |
| 2020 | $ 24.53B | $ 6.19B | $ 3.68B |
| 2019 | $ 22.31B | $ 8.31B | $ 2.43B |
| 2018 | $ 21.49B | $ 3.23B | $ 7.40B |
| 2017 | $ 19.97B | -$ 204M | $ 8.03B |
| 2016 | $ 21.22B | $ 2.73B | $ 6.03B |
| 2015 | $ 19.95B | $ 2.40B | $ 4.45B |
| 2014 | $ 19.61B | $ 2.39B | $ 4.82B |
| 2013 | $ 23.11B | $ 4.68B | $ 5.39B |
| 2012 | $ 22.60B | $ 4.08B | $ 5.68B |
| 2011 | $ 24.28B | $ 4.34B | $ 6.89B |
| 2010 | $ 23.07B | $ 5.06B | $ 6.72B |
| 2009 | $ 21.83B | $ 4.32B | $ 4.49B |
| 2008 | $ 20.37B | -$ 2.07B | $ 5.92B |
| 2007 | $ 18.63B | $ 2.95B | $ 4.83B |
| 2006 | $ 15.69B | $ 2.66B | $ 3.89B |
| 2005 | $ 14.64B | $ 1.97B | $ 5.03B |
| 2004 | $ 13.85B | $ 1.81B | $ 7.46B |
| 2003 | $ 12.58B | $ 2.56B | $ 3.71B |
| 2002 | $ 11.07B | $ 2.70B | $ 3.65B |
| 2001 | $ 11.54B | $ 2.78B | $ 3.73B |
| 2000 | $ 10.86B | $ 3.05B | $ 4.61B |
| 1999 | $ 10.00B | $ 2.72B | $ 3.83B |
| 1998 | $ 9.23B | $ 2.09B | $ 1.49B |
| 1997 | $ 7.98B | -$ 385M | $ 1.94B |
| 1996 | $ 6.99B | $ 1.52B | $ 813M |
| 1995 | $ 6.76B | $ 2.29B | $ 999M |
| 1994 | $ 5.71B | $ 1.28B | $ 536M |
| 1993 | $ 6.45B | $ 480M | $ 539M |
| 1992 | $ 6.16B | $ 708M | $ 432M |
| 1991 | $ 5.72B | $ 1.31B | $ 479M |
| 1990 | $ 5.19B | $ 1.12B | $ 350M |
| 1989 | $ 4.17B | $ 939M | $ 323M |
| 1988 | $ 4.06B | $ 761M | $ 761M |
| 1987 | $ 3.64B | $ 643M | $ 1.03B |
| 1986 | $ 3.72B | $ 558M | $ 486M |
| 1985 | $ 3.27B | $ 517M | $ 406M |
Eli Lilly and Company fundamental performance
Between 2020 and 2025, revenue grew from $ 24.53B to $ 65.17B and net income grew from $ 6.19B to $ 20.63B. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 19.95B to $ 65.17B and net income grew from $ 2.40B to $ 20.63B. Revenue increased in 9 of those 10 years; net income in 6.
Eli Lilly and Company currently holds a 20-year HDB Score of 6.7 out of 10. How the HDB Score is calculated.
Membership
Continue LLY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
